All News

EULAR flags

Vasculitis Updates: Glucocorticoid use in AAV and GCA

2026 EULAR Press Release

Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.

Read Article
EULAR flags

Understanding Comorbidities in RMD

2026 EULAR Press Release

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.

Read Article
EULAR conference

Day 1 Report from EULAR 2026

Jack Cush, MD

The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.

Read Article
safety data

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

Read Article
🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST

Jiha Lee JihaRheum ( View Tweet)

Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810

Jiha Lee JihaRheum ( View Tweet)

Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow. Average age 28! 87%female, only 7 % with psychiatric referral! Retrospective 15 pts. https://t.co/241SE6O395

Links:

Bella Mehta bella_mehta ( View Tweet)
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206

Jiha Lee JihaRheum ( View Tweet)

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Rosnilimab works!! #PD1 agonist In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA #EULAR2026 @RheumNow #OP0202 #EULARbest https://t.co/Jz92npXdgd

Links:

Janet Pope Janetbirdope ( View Tweet)
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068

Jiha Lee JihaRheum ( View Tweet)

Izokibep IL-17A Affibody PsA 343 pts RCT PBO crossover wk16 52 wks data ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52% No diff between QW vs Q2W AE Injection-site reactions, URTIs most common No new safety signals Looks like any other IL17Ai to me #EULAR2026 #OP073 https://t.co/WiHT8Plitn

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
💉 Risankizumab durable in #PsA? #POS0047 3 RCT n=964 KEEPsAKE Yes! ACR50 ~37% & MDA ~34% @w244 no new safety signals 💪 #EULAR2026 @RheumNow https://t.co/911Fi9vxfP

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×